Exclusive: Fresenius nears deal to acquire Akorn - sources
April 24, 2017 at 12:45 PM EDT
(Reuters) - German healthcare conglomerate Fresenius SE & Co KGaA is close to acquiring generic drugmaker Akorn Inc in an all-cash deal valuing the company at more than $4 billion, people familiar with the matter said on Monday.
